STVN
Stevanato GroupANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-05
Current thesis
The Q2 report supports a constructive operating trend: strong BDS growth, rising high-value-solution mix, margin expansion, biologics and GLP-1 exposure, progress at Fishers and Latina, and a regulatory approval for a customer product incorporating Alina. The Balda divestiture also sharpens the strategic focus on higher-value solutions.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Engineering revenue declined 2% and management cited elongated sales cycles and project phasing.
Momentum
74
Value
53
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.40 · Bull $27.00 · Bear $17.00
Data freshness
Prices
As of 2026-08-05
Fundamentals
As of 2026-08-05 • Vendor: Data Vendor v1
Scores
As of 2026-08-05 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-08-05
Investment thesis
As of 2026-08-05
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $25.17
Why
Momentum74 · Δ7d +17.6
Value53 · Δ7d +0.1
Sentiment77 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
74
10% active weight
Current posture
7d trendSoftening
Δ7d
+17.6
Δ21d
+40.4
Value
53
40% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.5
Sentiment
77
49% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 74.0 / Value 53.2 / Sentiment 76.8
Fundamentals (TTM)As of 2026-08-05
Fundamentals (TTM)
As of 2026-08-05
Market Cap
$5.49B
Beta
0.58
Shares Out
273M
P/E (TTM)
34.9
P/S (TTM)
4.65
P/FCF (TTM) · Derived
-482.01
Rev YoY
+18.5%
EPS YoY
+17.4%
Gross Margin
+28.1%
Op Margin
+16.7%
Net Debt
$397.32M
Current Ratio
1.63
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology